The Allen Institute has extended its contract with the Coriell Institute for Medical Research for the storage and distribution of its Allen Cell Collection, a cutting-edge collection of gene-edited human induced pluripotent stem cell lines. This collection was launched in 2016 with five cell lines, and since has grown to include more than 40 lines. The new agreement will continue this relationship for an additional three years.
read moreShoghag Panjarian, PhD, a research scientist at the Coriell Institute for Medical Research, has been awarded a grant from the W. W. Smith Charitable Trust to support her search for epigenetic factors that contribute to the development and growth of breast cancer.
read moreThe samples – a total of 351 lymphoblastoid cell lines – are associated with a long-term study of aging known as The 90+ Study. The 90+ Study is administered by a team of scientists from the University of California Irvine and its goal is to investigate the basic lifestyle and biological factors which underlie advanced aging.
read moreThe five-year award will support the NINDS Human Genetics Resource Center, a collection of biological samples and corresponding demographic, clinical, and genetic data made available to qualified researchers around the world. This repository includes samples from subjects with various diseases – such as cerebrovascular disease, dystonia, epilepsy, motor neuron disease, parkinsonism, and Tourette Syndrome.
read moreA pair of new induced pluripotent stem cell lines has been added to the Aging Cell Repository, a collection of biomaterials sponsored by the National Institute on Aging (NIA).
read moreThe Coriell Institute for Medical Research will support one of the two new centers tasked with generating new reference sequences of the human genome.
read morePatients with acute myeloid leukemia (AML), a leukemia which arises from bone marrow tissue, often see remission following their initial treatment, but for patients whose cancer returns, there are few options. One such option is guadecitabine, a novel DNA hypomethylating drug which slows problematic changes to a person’s epigenetic profile, but the drug is ineffective in a select number of relapsed or refractory AML patients and there has not been a way to determine who stands to benefit and who does not.
read moreThe Coriell Institute for Medical Research is now participating in a prestigious SU2C Catalyst® grant from Stand Up To Cancer for the study of epigenetic therapy in treating urothelial cancer, a common form of cancer typically found in the bladder. Part of the project grant was moved to Coriell following its hiring of Jean-Pierre Issa, MD, as its new President and Chief Executive Officer.
read moreTwo new lines of induced pluripotent stem cells are now available to researchers through the National Institute on Aging’s Aging Cell Repository, housed and distributed by the Coriell Institute for Medical Research. The addition of these two lines brings the total number of highly-characterized iPSC lines offered through this collection to five.
read moreThe Coriell Institute for Medical Research will attend this year’s American College of Medical Genetics and Genomics’ (ACMG) Annual Clinical Genetics Meeting. This year’s event is held in Seattle, Washington from April 2 until April 6.
read more